Navigation Links
Commercial Manufacturing of H1N1 'Swine Flu' Vaccine Underway
Date:6/15/2009

Approximately 100,000 doses can be manufactured per week

MERIDEN, Conn., June 15 /PRNewswire/ -- Protein Sciences Corporation (PSC) announced that today it commenced manufacturing of a vaccine to protect humans against the H1N1 "swine flu" virus. The Company estimates that it can produce 100,000 doses this week and at least 100,000 doses per week thereafter. The vaccine, called PanBlok(R), is made using PSC's proprietary baculovirus and insect cell manufacturing technology. PSC believes that PanBlok is the first and only vaccine that could be used to protect against the escalating worldwide pandemic, at least for the next few months.

Following bulk production, the vaccine will undergo routine quality tests, the longest of which will require up to one month. Thus, by mid-July the vaccine should be ready to be used in clinical trials and/or for vaccinations in countries that grant regulatory clearance.

Daniel D. Adams, Chairman, President and CEO stated, "We are in the process of transferring our proprietary manufacturing technology to facilities in other countries and we are setting up a foundation to ensure vaccine availability for U.N. member countries consistent with the commitment we made to the World Health Organization and the United Nations in Geneva, Switzerland on May 19, 2009." He added, "Using our proprietary technology, licensees could be producing vaccine in as little as two to three weeks if they are currently working with insect cells and in a few months if they are now producing monoclonal antibodies."

PSC also announced that it will begin shipping H1N1 protein for research use to customers with pre-orders. Orders may be placed on the Company's website (www.proteinsciences.com).

PSC is in late stage discussions with various parties in the United States and abroad to conduct the first hu
'/>"/>

SOURCE Protein Sciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. ADVENTRX Appoints Vice President of Commercialization
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
7. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
8. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
9. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 15, 2014  Ascendis Pharma A/S, a ... to address significant unmet medical needs, today announced ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  This interim analysis consists of 25 patients, ... in the study, completing all six months of ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 The ... million in 2013, and is expected to grow ... 2019. , Browse through the TOC of the ... industry trends and segments, with help of various ... The global DNA Microarray market consists of instrument, ...
(Date:12/13/2014)... 2014 QuickSTAT is making significant investments ... Chain capabilities, and is delighted to announce the opening ... serve Life Science clients in the region. , QuickSTAT ... warehouse, will provide 24/7 transportation and logistics services, as ... patient-clinical specimens, API, following IATA rules and EU GDP ...
(Date:12/13/2014)... ANTONIO , Dec. 12, 2014  Janssen Research ... data at the San Antonio Breast Cancer Symposium (SABCS) ... plus best supportive care (BSC) versus BSC when used ... receiving standard chemotherapy. This non-inferiority trial did not meet ... 15 percent or greater increase in the risk of ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
... to Launch into High Growth Brazilian Market for ... Aesthera announced today the receipt of ANVISA clearance ... platforms in Brazil. ANVISA (Agencia Nacional de ... and regulatory agency charged with clearing all applications ...
... Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") ... to date this year and guidance on its projected financial ... , ... 4.60 million (US $0.68 million), representing a 127 percent increase ...
... , Connecticut MORRISVILLE, N.C., May 20 Asymchem ... and Drug Products to the pharmaceutical industry, with sites in ... award by Pfizer Inc. as the 2008 Top Intermediates CMO ... center on May 1, 2009. The award was the first ...
Cached Biology Technology:Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 2Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 3Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 2Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 3Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... two Texas AgriLife Research scientists later turned into a ... female sheep. Female sheep (ewes) are an agriculturally important ... for studying the physiology of human pregnancy, the researchers ... treat male erectile dysfunction, enhanced blood flow in pregnant ...
... scientists have warned of the possible negative health effects ... from plastic water bottles and food packaging to sunglasses ... disorders, obesity, abnormal brain development as well as breast ... Drug Administration announced that it was concerned about "the ...
... new way of preventing potentially harmful plasticizers the source ... of the most widely used groups of plastics. The advance ... plastics that are safer than those now used in packaging, ... is in ACS, Macromolecules , a bi-weekly journal. ...
Cached Biology News:Study shows male erectile dysfunction drug enhances fetal growth in female sheep 2Mother's exposure to bisphenol A may increase children's chances of asthma 2